CRYSTALLIZED OXALATE DECARBOXYLASE AND METHODS OF USE
Oxalate decarboxylase crystals, including stabilized crystals, such as cross-linked crystals of oxalate decarboxylase, are disclosed. Methods to treat a disorder associated with elevated oxalate concentration using oxalate decarboxylase crystals are also disclosed. Additionally disclosed are methods of producing protein crystals.
1 . A pharmaceutical composition comprising an oxalate decarboxylase crystal.
2 . The composition of claim 1 , wherein said crystal is more active than a soluble form of oxalate decarboxylase.
3 . The composition of claim 2 , wherein the activity of said crystal is at least about 100% higher than the activity of the soluble form at pH 4.
4 . The composition of claim 1 , wherein the oxalate decarboxylase crystal is crosslinked with a cross-linking agent and has at least about 100% of the activity of a soluble form of oxalate decarboxylase.
5 . The composition of claim 4 , wherein the oxalate decarboxylase crystal is crosslinked with a cross-linking agent and has at least about 150% of the activity of the soluble form of oxalate decarboxylase.
6 . The composition of claim 4 , wherein said cross-linking agent is glutaraldehyde.
7 . The composition of claim 6 , wherein the oxalate decarboxylase crystal is crosslinked with about 0.02% to about 1.5% (w/v) glutaraldehyde.
8 . The composition of claim 7 , wherein the crystal is cross-linked with about 0.5% 20 (w/v) glutaraldehyde.
9 . A method of reducing oxalate in a mammal, the method comprising administering a composition comprising oxalate decarboxylase crystals to the mammal in an amount sufficient to reduce the oxalate.
10 .- 17 . (canceled)
18 . A method of treating a disorder associated with elevated oxalate concentration in a mammal, the method comprising administering oxalate decarboxylase crystals to the mammal in an amount sufficient to reduce one or more symptoms associated with the disorder.
19 .- 33 . (canceled)